Trump pharmaceuticals announcement "threatens to unleash a pharmageddon that could cost the NHS billions in extra medication cost"

Trump’s late‑night Truth Social manifesto threatens to unleash a pharmageddon that could cost the NHS billions in extra medication costs, just as budgets are tightened. This is sadly not hyperbole but a fair reading of the proposed executive order, as this plan would peg US prices to the lowest charged in any peer economy, leaving pharmaceutical providers to find new ways of making up for lost revenue. As it stands, UK medication prices already sit at the bottom of league tables, leaving them ripe for potential price increases to claw back profitability. Just a 4% uplift in branded‑drug costs over the next spending‑review window would land a more than £1bn blow to the NHS, as the Treasury tries to desperately reduce funding. As a consequence, what the Trump Administration may pitch as a populist victory to US voters will result in a stealth tax on British patients, with every forced discount across the Atlantic inviting manufacturers to stiffen prices inside the NHS.